Construct Optimization Enables Oncolytic Virus-Mediated Functional Membrane Localization of Calreticulin and Macrophage Reprogramming.

IF 4 3区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Human gene therapy Pub Date : 2026-05-01 Epub Date: 2026-02-19 DOI:10.1177/10430342261423100
Xinyuan Zhang, Shengfeng Xiong, Song Zhang, Yao Si, Zhoutong Dai, Teng Ji, Xiaoyuan Huang, Dong Chen, Fei Li, Fayong Hu, Xi Li
{"title":"Construct Optimization Enables Oncolytic Virus-Mediated Functional Membrane Localization of Calreticulin and Macrophage Reprogramming.","authors":"Xinyuan Zhang, Shengfeng Xiong, Song Zhang, Yao Si, Zhoutong Dai, Teng Ji, Xiaoyuan Huang, Dong Chen, Fei Li, Fayong Hu, Xi Li","doi":"10.1177/10430342261423100","DOIUrl":null,"url":null,"abstract":"<p><p>The recent evolution of oncolytic virotherapy has yielded viral platforms with enhanced tumor tropism and expanded engineering flexibility, thereby enabling not only direct oncolysis but also deliberate promotion of antitumor immune responses. Here, we systematically explore multiple insertion sites for calreticulin (CALR) within an oncolytic adenovirus, identifying the most optimal variant that exposes robust CALR on tumor cell membrane and functionally motivates macrophages in addition to directly mediating tumor cell lysis. Mechanistically, this variant incorporates a precise deletion within the <i>E1A CR2</i> domain (920-946 bp), enabling selective replication in retinoblastoma-deficient tumor cells. Furthermore, the <i>E3-gp19k</i> region has been replaced with an exogenous Cytomegalovirus (CMV) promoter to achieve precise regulation of CALR overexpression and diminish systemic toxicity. Functionally, by bulk-RNA-Seq, we demonstrate that oncolytic adenovirus (oAd)-CMV-CALR transfection induces endoplasmic reticulum stress, as evidenced by upregulation of phosphorylated eIF2α, which facilitates the translocation of CALR to the plasma membrane. Via <i>ex vivo</i> coculture assays, we validate that oAd-CMV-CALR transfection enhances the phagocytic capacity of M2 macrophages and promotes their repolarization toward an M1-like phenotype. These findings are further validated in patient-derived ovarian cancer spheroids, underscoring the translational potential of our approach. <i>In vivo</i>, oAd-CMV-CALR suppresses Hepa1-6 xenograft growth, boosts CD8<sup>+</sup> T-cell infiltration, and exhibits favorable safety. Collectively, our findings highlight oAd-CMV-CALR as a potential therapeutic approach to modulate the tumor microenvironment and improve cancer immunotherapy outcomes.</p>","PeriodicalId":13007,"journal":{"name":"Human gene therapy","volume":" ","pages":"412-424"},"PeriodicalIF":4.0000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10430342261423100","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The recent evolution of oncolytic virotherapy has yielded viral platforms with enhanced tumor tropism and expanded engineering flexibility, thereby enabling not only direct oncolysis but also deliberate promotion of antitumor immune responses. Here, we systematically explore multiple insertion sites for calreticulin (CALR) within an oncolytic adenovirus, identifying the most optimal variant that exposes robust CALR on tumor cell membrane and functionally motivates macrophages in addition to directly mediating tumor cell lysis. Mechanistically, this variant incorporates a precise deletion within the E1A CR2 domain (920-946 bp), enabling selective replication in retinoblastoma-deficient tumor cells. Furthermore, the E3-gp19k region has been replaced with an exogenous Cytomegalovirus (CMV) promoter to achieve precise regulation of CALR overexpression and diminish systemic toxicity. Functionally, by bulk-RNA-Seq, we demonstrate that oncolytic adenovirus (oAd)-CMV-CALR transfection induces endoplasmic reticulum stress, as evidenced by upregulation of phosphorylated eIF2α, which facilitates the translocation of CALR to the plasma membrane. Via ex vivo coculture assays, we validate that oAd-CMV-CALR transfection enhances the phagocytic capacity of M2 macrophages and promotes their repolarization toward an M1-like phenotype. These findings are further validated in patient-derived ovarian cancer spheroids, underscoring the translational potential of our approach. In vivo, oAd-CMV-CALR suppresses Hepa1-6 xenograft growth, boosts CD8+ T-cell infiltration, and exhibits favorable safety. Collectively, our findings highlight oAd-CMV-CALR as a potential therapeutic approach to modulate the tumor microenvironment and improve cancer immunotherapy outcomes.

结构优化实现溶瘤病毒介导的钙网蛋白功能膜定位和巨噬细胞重编程。
溶瘤病毒疗法的最新发展已经产生了具有增强的肿瘤趋向性和扩大的工程灵活性的病毒平台,从而不仅可以直接溶瘤,还可以故意促进抗肿瘤免疫反应。在这里,我们系统地探索了溶瘤腺病毒中钙网蛋白(CALR)的多个插入位点,确定了最优的变体,该变体在肿瘤细胞膜上暴露出强大的CALR,并在功能上激发巨噬细胞,并直接介导肿瘤细胞裂解。从机制上讲,该变体包含E1A CR2结构域(920-946 bp)的精确缺失,能够在视网膜母细胞瘤缺陷肿瘤细胞中选择性复制。此外,E3-gp19k区域已被外源性巨细胞病毒(CMV)启动子取代,以实现CALR过表达的精确调控并降低全身毒性。功能上,通过bulk-RNA-Seq,我们证明了溶瘤腺病毒(oAd)-CMV-CALR转染诱导内质网应激,正如磷酸化的eIF2α上调所证明的那样,这促进了CALR向质膜的易位。通过体外共培养实验,我们验证了转染oAd-CMV-CALR可增强M2巨噬细胞的吞噬能力,并促进其向m1样表型的复极化。这些发现在患者衍生的卵巢癌球体中得到进一步验证,强调了我们方法的转化潜力。在体内,oAd-CMV-CALR抑制Hepa1-6异种移植物生长,促进CD8+ t细胞浸润,并表现出良好的安全性。总的来说,我们的研究结果强调了oAd-CMV-CALR作为一种潜在的治疗方法来调节肿瘤微环境和改善癌症免疫治疗结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human gene therapy
Human gene therapy 医学-生物工程与应用微生物
CiteScore
6.50
自引率
4.80%
发文量
131
审稿时长
4-8 weeks
期刊介绍: Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书